Myovant and Pfizer Publish the Results of Relugolix Combination Regimen in P-III LIBERTY Studies in NEJM
Shots:
- The P-III LIBERTY 1 & 2 studies involve assessing of relugolix (40mg) + estradiol (1.0mg) & norethindrone acetate (0.5mg) vs PBO in women with uterine fibroids
- The results showed response rates in menstrual blood loss (73.4% & 71.2%) vs (18.9% & 14.7%) @24wks; 84.3% reduction in menstrual blood loss from baseline; maintained bone mineral density; reduction of pain; improvement in anemia and was well tolerated respectively
- Data from LIBERTY 1& 2 study- in addition to the 28-week long-term extension study- were included in the NDA) for relugolix combination tablet with anticipated PDUFA date as Jun 01- 2021
Ref: Pfizer | Image: Myovant
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com